Corvus Pharmaceuticals (CRVS)

• Market cap: $548M
• 1 day: -4.68%
• 5 days: -1.87%
• 1 month: -8.82%
• 3 months: 4.26%
• 6 months: 84.42%
• Year to date: 35.17%
• 1 year: 35.17%
• 5 years: 94.18%
• 10 years: -48.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31